Composite Insurer Licensing 2026: Premium Shift Patterns for Indian Brokers

The composite insurer licence was the most-discussed insurance reform of 2025, but it did not make it into law. The Sabka Bima Sabki Raksha (Amendment of Insurance Laws) Act, 2025, passed by Parliament on 17 December 2025 and assented later that month, excluded the composite licence provision that would have let a single insurer write both life and non-life business under one entity. The reform that did pass raised the foreign direct investment cap to 100 percent, gave IRDAI disgorgement and rule-making powers, eased intermediary registration, and granted LIC additional operational autonomy. The composite licence, reduced entry capital norms, and captive provisions were left out.

That outcome matters for brokers because a lot of 2025 planning assumed composite licensing was coming. It is not, at least not under the 2025 Act. The structural separation that has defined Indian insurance for decades remains in force: life insurers write life business, general insurers write non-life, and standalone health insurers write health under the health licence. A corporate buyer that wants to consolidate its full employee benefits programme with one insurer still cannot, because no single insurer can hold both the group life licence and the group health and group personal accident licences in one entity.

So the honest read for 2026 is that the composite-driven premium shift many brokers were positioning for has not arrived. Premium flows across Indian commercial insurance continue to follow the established line-by-line placement logic. The genuine structural change of the cycle is the 100 percent FDI opening, which affects ownership and capital rather than the licence structure that governs how an employee benefits programme is split across insurers.

The practical broker takeaway is to reset client advisory away from composite consolidation and back to the durable questions that actually drive placement: best-of-breed selection across separate life, general, and standalone health insurers, panel discipline, and the negotiating leverage a broker builds by placing a large multi-line account well across multiple specialist carriers. The composite question can still come up in client conversations because it was so heavily trailed in the press; the broker's job now is to explain accurately that it did not become law and to refocus the buyer on the levers that are real.

The reform that did pass in the 2025 Act will shape the insurer landscape brokers place into, even though it does not touch the life and non-life separation. Understanding what actually changed helps brokers brief clients accurately rather than carrying forward last year's composite-licence assumptions.

The headline change is the foreign direct investment cap moving from 74 percent to 100 percent. Foreign insurers and global capital can now wholly own an Indian insurance company, subject to the conditions IRDAI attaches. Over the coming years this is likely to bring additional capacity and new entrants, particularly in specialty and commercial lines where global carriers carry deep underwriting expertise. For brokers, more carriers and more capacity generally mean more placement options and stronger competition on terms, especially on hard-to-place commercial risks. The change is a capital and ownership reform, not a product or licence reform, so it expands who can compete rather than changing what any single insurer is allowed to write.

The Act also strengthened IRDAI's regulatory toolkit. The regulator gained disgorgement powers to recover wrongful gains, simplified intermediary registration, and a higher threshold for equity transfers that require approval. These provisions tighten conduct supervision and make it administratively easier to register and operate as an intermediary, which is directly relevant to broking firms managing their own licensing and that of their sub-brokers.

For brokers advising corporate clients, the FDI change is worth flagging in renewal conversations for one reason: it may improve capacity and competition on large or complex placements over the next few renewal cycles. It does not, however, let a buyer consolidate group life and group health with a single insurer. That distinction is exactly where brokers add value right now, by separating the reform that happened (ownership liberalisation) from the reform that did not (composite licensing) and advising on the basis of the structure that is actually in force.

The composite licence had been under discussion for years and was expected by much of the industry to feature in the 2025 reforms. It was ultimately not cleared for inclusion in the Act. Brokers do not need the internal policy rationale to advise clients well, but they do need a realistic view on whether it returns, because that view shapes how much weight to put on composite scenarios in multi-year client strategy.

The practical position for 2026 is straightforward. A composite licence is not available, no insurer can apply for one, and there is no operational composite insurer in the Indian market. Any future move toward composite licensing would require fresh legislation or a further amendment, followed by an IRDAI framework, followed by insurer restructuring and licensing. That is a multi-step, multi-year sequence even if the policy direction were revived. Brokers should therefore treat composite licensing as a possible long-horizon development rather than a current or near-term placement factor.

This has a concrete consequence for client advisory. If a corporate client raises composite consolidation because they read about it during the 2025 legislative cycle, the accurate answer is that the provision was dropped and the existing licence separation continues. Brokers should not build placement recommendations, panel decisions, or multi-year benefits strategy on the assumption that a composite insurer will be available. The defensible planning base is the structure in force: separate life, general, and standalone health insurers, with employee benefits programmes split across them.

What brokers can usefully monitor is the regulatory and legislative agenda, because the topic has clearly not disappeared from industry discussion. Tracking IRDAI exposure drafts, Finance Ministry consultations, and any future amendment proposals is reasonable forward intelligence. But monitoring a possible future is different from planning around a present reality, and the present reality is that there is no composite licence.

With composite consolidation off the table, the premium flows that brokers manage continue to follow line-by-line placement logic. It is worth restating that logic clearly, because it is the framework brokers should be advising within rather than the composite framework that did not materialise.

Employee benefits remain split by licence. Group health, group personal accident, and other non-life benefits are placed with general insurers or standalone health insurers. Group term life and employer-employee life arrangements are placed with life insurers. A corporate buyer running a full benefits programme is therefore working with at least two insurer relationships by structural necessity, not by choice. The broker's value is in coordinating those relationships, aligning renewal timing where possible, and negotiating each line on its own merits.

Commercial property, marine, and engineering continue to be placed with general insurers on the strength of line-specific underwriting: risk surveys, sum insured adequacy, peril analytics, and reinsurance capacity. These are exactly the lines where best-of-breed carrier selection matters most, and where the broker's panel breadth and placement skill drive the outcome. The 100 percent FDI opening is most likely to add competition here over time as global specialty carriers expand their Indian presence.

Commercial liability lines, including commercial general liability, product liability, professional indemnity, and directors and officers, are placed on claims-handling depth, defence panel quality, and capacity for large limits. Buyer decisions on these lines turn on capability, not on consolidation.

Commercial motor and fleet placement is driven by service factors: workshop network, surveyor availability, and claims processing speed. Cyber, parametric, and specialty lines are placed on specialised capability and capacity.

The broker takeaway is that there is no composite shortcut to managing a multi-line account. Strong placement comes from disciplined panel management, line-level underwriting knowledge, and the negotiating leverage that a well-placed multi-line account creates across separate specialist carriers. That has not changed, and under the 2025 Act it is not going to change.

Corporate clients absorbed a lot of composite-licence coverage during 2025, and some carried away the impression that single-insurer consolidation of employee benefits was about to become possible. Part of the broker's job in 2026 renewal conversations is to correct that impression accurately and refocus the client on real levers.

The correction should be factual and brief: the composite licence provision was dropped from the Insurance Amendment Act 2025, no composite insurer exists, and group life and group health therefore continue to be placed with separate insurers. There is no need to speculate on why it was left out; the operative point for the client is that the placement structure they are planning around is the existing separated structure.

From there, the broker should redirect the conversation to what the client can actually optimise. First, coordinated renewal management across the separate life and non-life lines: aligning renewal dates where feasible, running census data once and using it across placements, and presenting a consolidated programme view to the client even though the underlying policies sit with different insurers. The broker can deliver an integrated experience operationally even though a single contract is not available.

Second, best-of-breed selection. Because consolidation is not on the table, the buyer's interest is best served by selecting the strongest carrier for each line on price, claims handling, and service, rather than accepting a weaker carrier for the sake of a single relationship. This is the natural advisory posture under the current structure, and it is one brokers should articulate confidently.

Third, the FDI-driven capacity outlook. Where relevant, the broker can note that 100 percent foreign ownership may bring additional capacity and competition to commercial and specialty lines over coming cycles, which could benefit the client on hard-to-place risks. This is a genuine, accurate forward point, in contrast to the composite scenario that did not happen.

The broker should document the advice given, including the correction on composite licensing, as part of the suitability record under IRDAI broker regulations. Documenting that the client was advised on the basis of the structure actually in force protects both the client and the broker.

The absence of a composite licence preserves the competitive landscape that specialist insurers and brokers already operate in, while the 100 percent FDI opening introduces a different kind of competitive pressure over the medium term. Both effects are worth understanding for firms setting strategy.

For specialist general insurers, standalone health insurers, and life insurers, the immediate effect of the composite licence being dropped is that there is no integrated composite competitor capturing employee benefits books on a single contract. The line-by-line market in which each specialises continues. The strategic pressure these insurers face comes not from composite consolidation but from the prospect of new and better-capitalised entrants enabled by 100 percent foreign ownership. The defensible response is the same as it always was: deep line-specific capability, responsive claims handling, and pricing discipline, now sharpened by the expectation of stronger competition over the next few cycles.

Standalone health insurers are no longer exposed to the composite-consolidation risk that 2025 commentary highlighted, because no insurer can bundle health with life under one licence. Their competitive task is to keep differentiating on TPA network depth, wellness integration, claims experience analytics, and industry-specific product design against other non-life and standalone health carriers.

Specialist brokers focused on employee benefits retain a clear role: coordinating the separate life and non-life placements, running the benefits analytics, and managing TPA and employee communication. Because consolidation is not available, the broker's coordination value is structural rather than optional. Brokers with strong benefits-design and TPA-management capability are well positioned regardless of the licence debate.

The broader market implication is continuity rather than disruption on the licence structure, combined with a gradual capacity and competition shift driven by foreign ownership liberalisation. Boards of mid-tier insurers and specialist brokers should set strategy against that realistic picture rather than against the composite scenario that did not become law.

Even with composite licensing off the table, several developments through FY2026-27 will shape the commercial insurance market brokers place into. Tracking these gives brokers an evidence base for advising clients and updating panel strategy on what is actually happening rather than on what was expected to happen.

The first is the pace and shape of new entry under 100 percent FDI. Watch which global carriers move to take full ownership of Indian operations or set up new entities, and which lines they target. Specialty and commercial lines are the likeliest focus, and new capacity there would directly affect placement options for brokers.

The second is IRDAI's use of its strengthened powers. The Act gave IRDAI disgorgement and rule-making powers and eased intermediary registration. Watch the circulars and frameworks IRDAI issues to operationalise these, particularly anything affecting broker and sub-broker registration, conduct supervision, and intermediary compliance obligations.

The third is whether composite licensing returns to the legislative agenda. The topic has been raised repeatedly over years and was a prominent omission in 2025. Any fresh consultation, exposure draft, or amendment proposal would be the earliest signal that the question is reopening. Until such a signal appears, brokers should continue planning on the separated structure.

The fourth is capacity and pricing on commercial lines. As FDI-driven entry develops, watch for changes in capacity and terms on commercial property, engineering, marine, liability, and specialty placements. Improved capacity on hard-to-place risks would be a tangible client benefit a broker can surface in renewal conversations.

The fifth is standalone health and group benefits competition. With composite bundling unavailable, competition among non-life, standalone health, and life insurers for the employee benefits book continues on capability and service. Watch product launches, TPA network investments, and pricing movements as competitive intelligence for benefits placements.

The sixth is broker industry capability, including consolidation and technology investment, which shapes the analytical depth brokers bring to multi-line client advisory. The broker performance data IRDAI publishes provides one measure of how the broking market is evolving.

The accurate framing for 2026 is that the composite premium shift did not happen because the licence was not enacted. The real structural reform of the cycle is the move to 100 percent FDI, and the durable broker discipline is best-of-breed placement across separate specialist insurers. Brokers who advise clients on that basis, rather than on a composite scenario that the 2025 Act removed, will give better and more defensible advice.